AGEN
$2.50
Agenus
$.02
.81%
AGEN
Earnings Whisper ®
N/A
3rd Quarter September 2019
Consensus:  ($0.38)
Revenue:  $5.37 Mil
Tuesday
Nov 5
7:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when AGEN reports earnings?
Beat
Meet
Miss

Where is AGEN's stock price going from here?
Up
Flat
Down
Stock chart of AGEN
Analysts
Summary of analysts' recommendations for AGEN
Score
Grade
Pivots
Resistance
$2.73
$2.67
$2.58

$2.52

Support
$2.43
$2.37
$2.28
Tweet
Growth
Description
Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company's product line includes Oncophage vaccine, a patient-specific therapeutic cancer vaccine. The Company is also developing Prophage, patient-specific therapeutic cancer vaccine; QS-21, vaccine adjuvant; and HerpV, a polyvalent off-the-shelf therapeutic heat shock protein-based vaccine for treatment of genital herpes which are all in the clinical testing stages. Agenus Inc. is headquartered in Lexington, Massachusetts.
Peers
BiogenGilead SciencesBluebird BioAmgenNeurocrine BiosciencesSeattle GeneticsQiagen N.V.RepligenBioCryst PharmaceuticalsNovavax